Dissecting the biology of mTORC1 beyond rapamycin

Area of Science:

• Biochemistry
• Cell Biology
• Aging Research

Background:

• Rapamycin extends lifespan by inhibiting mechanistic target of rapamycin complex 1 (mTORC1), but its inhibitory effects are partial.
• Existing mTOR kinase inhibitors like Torin-1 can affect mTORC2, limiting their specificity.
• Understanding precise mTORC1 regulation is crucial for elucidating aging and metabolic processes.

Purpose of the Study:

• To characterize a novel, third-generation mTOR inhibitor, RapaLink1, with high specificity for mTORC1.
• To compare the efficacy of RapaLink1 with rapamycin in inhibiting mTORC1 activity and its downstream effects.
• To investigate the distinct roles of mTORC1 and mTORC2 in cellular metabolism and organismal stress resistance.

Main Methods:

• Utilized RapaLink1, a selective mTORC1 inhibitor, across various cellular and organismal models.
• Assessed mTORC1 substrate phosphorylation, cell proliferation, autophagy induction, and glucose metabolism.
• Examined starvation resistance in *Drosophila* following RapaLink1 treatment and genetic mTORC1 inhibition.

Main Results:

• RapaLink1 potently inhibited all tested mTORC1 substrates at low doses without affecting mTORC2 activity.
• RapaLink1 demonstrated superior mTORC1 inhibition compared to rapamycin, blocking cell proliferation and inducing autophagy.
• Differential effects of mTORC1 and mTORC2 on glycolysis and glucose uptake were observed.
• RapaLink1 and rapamycin exhibited opposing effects on starvation resistance in *Drosophila*.

Conclusions:

• RapaLink1 is a highly specific and potent inhibitor of mTORC1, offering advantages over existing drugs.
• mTORC1 and mTORC2 play distinct roles in cellular glycolysis and glucose metabolism.
• The complexity of mTORC1 signaling extends beyond rapamycin's inhibitory capacity, impacting organismal responses to stress and longevity.